Clinical trial · Observational
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Swiss Pediatric Inflammatory Bain Disease Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland opened for recruitment after that: Aarau, Basel, Bellinzona, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur and Zurich. The center in Fribourg is expected open for recruitment in 2025. The registry provides data for national and international monitoring and research. It supports research on inflammatory brain diseases in Switzerland and the exchange of knowledge between clinicians, researchers, and therapists. The registry aims to improve the treatment of children with inflammatory brain diseases and optimizing their health care and quality of life.
Conditions
Conditions (18)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Disseminated Encephalomyelitis | — | UNRESOLVED | — |
| Anti-AMPAR-1/2 Associated Autoimmune Encephalitis | — | UNRESOLVED | — |
| Anti-CASPR-2 Associated Autoimmune Encephalitis | — | UNRESOLVED | — |
| Anti-GABAR-1/2 Associated Autoimmune Encephalitis | — | UNRESOLVED | — |
| Anti-GAD65 Associated Autoimmune Encephalitis | — | UNRESOLVED | — |
| Anti-Lgi-1 Associated Autoimmune Encephalitis | — | UNRESOLVED | — |
| Anti-NMDAR Encephalitis | — | UNRESOLVED | — |
| CNS Lupus | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patient population
- description
- Children, adolescents and adults diagnosed with an IBrainD from 2005 onward and with disease onset before age 18, who are born, treated or living in Switzerland
Primary outcomes (18)
- measure
- Personal data
- timeFrame
- At registration (Life-long; Up to 80 years)
- description
- Registering patient's personal data
- measure
- Diagnosis
- timeFrame
- Until reaching of adulthood (0 to 18 years)
- description
- Diagnosis of IBrainD
- measure
- Age at diagnosis
- timeFrame
- Until reaching of adulthood (0 to 18 years)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 36 Years
Show eligibility criteria text
Inclusion Criteria: All patients living and/or treated in Switzerland with an IBrainD specified in the following list diagnosed from 2005 onward and with a disease onset before the age of 18. * Written informed consent by patients (and/or legal representative(s), if applicable) * Optic Neuritis * Transverse Myelitis * Acute disseminated encephalomyelitis * Multiple Sclerosis * Neuromyelitis Optica Spectrum Disorders * Myelin oligodendrocyte glycoprotein antibody-associated disease * Anti-NMDA-R Encephalitis * Anti-GAD65 Associated Autoimmune Encephalitis * Anti-AMPAR-1/2 Associated Autoimmune Encephalitis * Anti-Lgi-1 Associated Autoimmune Encephalitis * Anti-CASPR-2 Associated Autoimmune Encephalitis * Anti-GABAR-1/2 Associated Autoimmune Encephalitis * Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis * Hashimoto Encephalopathy * CNS Vasculitis * CNS Sarcoidosis * CNS Lupus * Rasmussen Encephalitis Exclusion Criteria: * Neurological symptoms due to infectious diseases of the CNS * Genetic/metabolic causes of central demyelinating diseases * Neurological symptoms due to Guillain-Barré-Syndrome
References
Publications (0)
Data not yet available